Plasmacytoid Dendritic Cells Are Crucial for the Initiation of Inflammation and T Cell Immunity In Vivo  by Takagi, Hideaki et al.
Immunity
ArticlePlasmacytoid Dendritic Cells Are Crucial
for the Initiation of Inflammation
and T Cell Immunity In Vivo
Hideaki Takagi,1 Tomohiro Fukaya,1 Kawori Eizumi,1 Yumiko Sato,1 Kaori Sato,1 Azusa Shibazaki,1 Haruna Otsuka,1
Atsushi Hijikata,2 Takashi Watanabe,2 Osamu Ohara,2 Tsuneyasu Kaisho,3 Bernard Malissen,4 and Katsuaki Sato1,5,*
1Laboratory for Dendritic Cell Immunobiology
2Laboratory for Immunogenomics
RIKEN Research Center for Allergy and Immunology, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
3Laboratory for Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, Yamadaoka 3-1, Suita,
Osaka 565-0871, Japan
4Centre d’Immunologie de Marseille-Luminy, Universite´ de la Me´diterranne´e, Case 906, Institut National de la Sante´ et de la Recherche
Me´dicale U631, and Centre National de la Recherche Scientifique UMR6102, 13288 Marseille Cedex 9, France
5Japan Science and Technology Agency, Precursory Research for Embryonic Science and Technology (PRESTO), 4-1-8 Hon-cho,
Kawaguchi, Saitama 332-0012, Japan
*Correspondence: katsuaki@rcai.riken.jp
DOI 10.1016/j.immuni.2011.10.014SUMMARY
Plasmacytoid dendritic cells (pDCs) are character-
ized as type I interferon-producing cells that engage
endosomal toll-like receptors (TLRs) and exclusively
express sialic acid binding Ig-like lectin (Siglec)-H.
However, their role in vivo remains unclear. Here we
report a critical role for pDCs in the regulation of
inflammation and T cell immunity in vivo by using
gene-targeted mice with a deficiency of Siglec-H
and conditional ablation of pDCs. pDCs were
required for inflammation triggered by a TLR ligand
as well as by bacterial and viral infections. pDCs
controlled homeostasis of effector and regulatory
CD4+ T cells. Upon antigenic stimulation and micro-
bial infection, pDCs suppressed the induction of
CD4+ T cell responses and participated in the initia-
tion of CD8+ T cell responses. Furthermore, Siglec-
H appeared to modulate the function of pDCs in vivo.
Thus, our findings highlight previously unidentified
roles of pDCs and the regulation of their function
for the control of innate and adaptive immunity.
INTRODUCTION
Plasmacytoid dendritic cells (pDCs), referred to as natural inter-
feron (IFN)-producing cells (IPCs), were originally discovered in
humans as a small subset of blood leukocytes specialized in
the secretion of high amounts of type I IFN in response to viruses,
and the murine counterparts of human IPCs were identified on
the basis of their phenotypic and functional characteristics
(Gilliet et al., 2008; Swiecki and Colonna, 2010). In contrast to
conventional DCs (cDCs), pDCs uniquely express toll-like
receptor (TLR) 7 and 9, intracellular receptors that recognize
single-stranded RNA or unmethylated CpG DNA within endoso-958 Immunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc.mal compartments (Gilliet et al., 2008; Swiecki and Colonna,
2010). Upon binding to their ligands, both TLRs recruit a cyto-
plasmic adaptor myeloid differentiation factor 88 (MyD88) and
initiate downstream signaling pathways, in which the activation
of the transcription factor nuclear factor kB (NF-kB) results in
the production of proinflammatory cytokines, whereas the acti-
vation of inhibitor of NF-kB (IkB) kinase (IKK)-a leads to phos-
phorylation and nuclear translocation of IFN regulatory factor-7
(IRF-7), a critical event for the production of type I interferon
(Hoshino et al., 2006).
pDCs are believed to provide an initial line of host defense
against viral infection mainly mediated by the production of
type I IFN (Gilliet et al., 2008; Swiecki and Colonna, 2010). In
addition, pDCs may act as antigen-presenting cells (APCs) to
exert a pleiotropic activating or inhibitory role in the regulation
of T cell-mediated adaptive immune responses and immunopa-
thogenesis (Salio et al., 2004; Ochando et al., 2006; Gilliet et al.,
2008; Irla et al., 2010). However, whereas observations in vitro
and ex vivo have suggested such functions, the precise role of
pDCs in vivo remains unclear. One way to analyze pDCs in vivo
is to delete them through treatment with monoclonal antibodies
(mAbs) that recognize molecules on their surface, such as Gr-1
(Asselin-Paturel et al., 2001; Yoneyama et al., 2005) or bone
marrow stromal antigen 2 (BST2) (Yoneyama et al., 2005; Kuwa-
jima et al., 2006; Shen and Iwasaki, 2006; Goubier et al., 2008).
However, this approach remains problematic because Gr-1
and BST2 are constitutively expressed on other immune cells
or expressed on most cell types after activation, resulting in
the depletion of additional cell types (Swiecki and Colonna,
2010). Therefore, the in vivo analysis of pDCs has been
hampered by the lack of a system that selectively eliminates
this cell subset during the inflammatory immune response.
Tobypass such limitations,weusedagene targeting approach
based on the diphtheria toxin receptor (DTR) (Jung et al., 2002;
Kissenpfennig et al., 2005) and targeted the gene coding for sialic
acid binding Ig-like lectin (Siglec)-H because it constitutes a
pDC-specific functional molecule. The corresponding strategy
allowed not only a deficiency of Siglec-H but also the specific
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pDCs play a crucial role in the regulation of inflammation and
T cell immunity in vivo and that Siglec-H controls pDCs function.
RESULTS
Deficiency of Siglec-H Modulates the Phenotype
and Function of pDCs
The analysis of gene expression among immune cells showed
that Siglech was predominantly expressed in pDCs but was
not present in other leukocytes including cDC subsets (data
not shown). Consistent with published reports (Blasius and
Colonna, 2006; Zhang et al., 2006), the cell surface expression
of Siglec-H was exclusively detected on BST2+ pDCs among
leukocytes in spleen (Spl), mesenteric lymph nodes (MLNs),
and bone marrow (BM) under steady-state conditions (data not
shown). Furthermore, BST2 was expressed on many cell types
after stimulation with CpG-A (a TLR9 ligand) in vivo, whereas
Siglec-H was expressed only on CD11c+CD11b–B220+ subsets
(data not shown).
To generate mice allowing specific elimination of pDCs in vivo,
we designed a targeting construct in which a cDNA encoding
the human DTR fused to sequences encoding enhanced green
fluorescent protein (EGFP) and equipped with an internal ribo-
some entry site (IRES) (Kissenpfennig et al., 2005) was inserted
into the 30 untranslated region of the Siglech gene to produce
Siglechdtr/dtr mice. Siglechdtr/dtr mice were born at the expected
frequencies, and homozygous mice were healthy.
To address the influence of the introduction of the IRES-DTR-
EGFP cassette into the Siglech locus, we compared the features
of pDCs between wild-type (WT) mice and Siglechdtr/dtr mice.
Unexpectedly, pDCs from Siglechdtr/dtr mice were deficient in
the transcriptional and cell surface expression of Siglec-H (Fig-
ure 1A and Figure S1A available online), possibly owing to inter-
ference with the transcriptional or posttranscriptional machinery.
Furthermore, pDCs from Siglechdtr/dtr mice displayed higher
amounts of CD11c and BST2 and lower amounts of B220 and
major histocompatibility complex class II (MHC II; I-A/I-E) mole-
cules than those from WT mice (Figure 1A), indicating that
Siglec-H affects the developmental process of pDCs in vivo.
We next examined TLR9-mediated cytokine production by
pDCs. Siglec-H-deficient pDCs produced higher amounts of
IFN-a and interleukin (IL)-12p40 than did WT pDCs (Figure 1B)
although there was no substantial difference in the subcellular
distribution of CpG-A-Cy5 and TLR9 in LAMP-1-positive late
endosomes and lysosomes (Figure S1B). In contrast, cDCs
from WT mice and Siglechdtr/dtr mice produced the same high
amounts of IL-12p40 after stimulation with CpG-A, although
they produced little or no IFN-a (Figure 1C).
We next investigated the signaling mechanism by which the
lack of Siglec-H resulted in increased cytokine production in
pDCs. Upon stimulation with CpG-A, there was no substantial
difference in the amounts of phosphorylated ERK, JNK, and
p38 between WT pDCs and Siglec-H-deficient pDCs (Figures
S1C and S1D). The activation of NF-kB, indicated by the phos-
phorylation and degradation of IkBa (Kaisho and Tanaka,
2008), was enhanced in Siglec-H-deficient pDCs as compared
with WT pDCs (Figures S1C and S1D). Furthermore, Siglec-H-
deficient pDCs showed greater phosphorylation of IKK-a andIthe association of IKK-a with IRF-7 after stimulation with CpG-
A than WT pDCs (Figures S1C and S1D). We also observed
that a Siglec-H mAb (Blasius and Colonna, 2006) slightly and
substantially suppressed the phosphorylation of IkBa and
IKK-a, respectively, in WT pDCs after stimulation with CpG-A
(Figure S1D). Therefore, the increased cytokine production
observed in pDCs deficient in Siglec-H appears to be due to
the enhanced TLR9-mediated activation of NF-kB and IKK-a.
Taken together, these results indicate that Siglec-H provides
an inhibitory signal for TLR9-mediated downstream cascades
to abrogate the cytokine production.
We determined next the influence of the deficiency of Siglec-H
on the ability of pDCs to prime CD4+ T cells through the MHC
II-dependent presentation of exogenous antigens and CD8+
T cells via the cross-presentation pathway, which is the capacity
to deliver antigens toMHCclass I (MHC I)molecules (Villadangos
and Young, 2008). Accordingly, we compared the capacity of
cDCs and pDCs from WT mice and Siglechdtr/dtr mice to present
soluble ovalbumin (OVA) protein or peptides via OVA-specific
T cell receptor (TCR) transgenic OT-II CD4+ T cells and OT-I
CD8+ T cells (Dudziak et al., 2007; Hildner et al., 2008). The ability
of pDCs to present OVA protein and peptide for the activation of
OT-II CD4+ T cells and OT-I CD8+ T cells was substantially lower
than that of cDCs inWTmice and Siglechdtr/dtr mice (Figures 1D–
1K) and was accompanied by lower amounts of MHC I and II,
CD40, and B7 family molecules (data not shown). When
compared with WT pDCs, Siglec-H-deficient pDCs showed a
reduced capacity to present OVA protein and peptide for priming
of OT-II CD4+ T cells (Figures 1D and 1E) because of the reduced
expression of MHC II, although they had little ability to present
OVA protein for the activation of OT-I CD8+ T cells, possibly
because of the defective cross-presentation pathway (Figures
1F and 1G). There was no major difference in the ability of
cDCs to prime OT-II CD4+ T cells and OT-I CD8+ T cells between
WT mice and Siglech-H-deficient mice (Figures 1H–1K).
Collectively, these results indicate that Siglec-H regulates the
ability of pDCs to prime CD4+ T cells and CD8+ T cells.
Inducible Ablation of pDCs in Mice
To validate the Siglechdtr/dtr mice in terms of DT-induced pDC
elimination, Siglechdtr/dtr mice received a single injection of DT,
and we monitored 2 days later the subsequent frequency and
the absolute number of pDCs among leukocytes in Spl, MLNs,
and BM. Treatment with DT at a dose of 1 mg per mouse almost
completely ablated pDCs among leukocytes in Spl, MLNs, and
BM in Siglechdtr/dtr mice, whereas this treatment had no effect
in WT mice (Figures 2A and 2B). Furthermore, the efficacy of
the ablation was greater in Siglechdtr/dtr mice than in Siglechdtr/+
mice (Figure 2A). In contrast, there was no change in the propor-
tion of cDCs and other leukocytes in Spls, MLNs, and BM as well
as the content of thymocytes in Siglechdtr/dtr mice as well as WT
mice after injectionwith DT (Figure 2C and data not shown). Such
DT-mediated ablation of pDCs occurred in a dose-dependent
manner (Figure 2D). Near-complete elimination was achieved
24 hr after the injection of DT in Siglechdtr/dtr mice, but cell
numbers gradually rebounded thereafter and had fully recovered
by day 10 (Figure 2E). Histological analysis of Siglechdtr/dtr mice
confirmed that pDCs disappeared after the injection of DT (Fig-
ure S2A), but there was no effect on the localization of CD11chimmunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc. 959
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Figure 1. Deficiency of Siglec-H Modulates the Phenotype and Function of pDCs
(A) The expression of cell surfacemolecules on pDCs fromWTmice and Siglechdtr/dtr mice was analyzed by flow cytometry. Data are represented by a histogram,
and numbers represent mean fluorescence intensity (MFI).
(B and C) pDCs (B) and cDCs (C) from WT mice and Siglechdtr/dtr mice were stimulated or not stimulated with CpG-A, and the production of IFN-a (left) and
IL-12p40 (right) was measured by enzyme-linked immunosorbent assay (ELISA).
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Role of pDCs in Innate and Adaptive ImmunitycDCs (Figure S2B) or CD209b+ marginal zone macrophages ex-
pressing intracellular Siglec-H (Figure S2C; Zhang et al., 2006).
Therefore, Siglechdtr/dtr mice provide the opportunity to
analyze the effect of a deficency of Siglec-H or the effect of
conditional ablation of pDCs in vivo, the two models referred to
as Siglec-H-deficient mice and pDC-ablated mice, respectively.
Siglec-H and pDCs Control TLR-Mediated Inflammatory
Responses In Vivo
We addressed the roles of Siglec-H and pDCs in the TLR-medi-
ated inflammatory response in vivo. Administration of CpG-A
caused serumproduction of IFN-a and IL-12p40 inWTmice (Fig-
ure 3A). Such production was markedly enhanced in Siglec-H-
deficient mice, whereas pDC-ablated mice exhibited a dramatic
reduction in serum cytokine amounts as comparedwithWTmice
(Figure 3A).
We also examined lethal shock triggered by CpG-A in
D-galactosamine (D-GalN)-sensitized mice. WTmice died within
24 hr after the administration of CpG-A plus D-GalN with a
marked elevation in serum concentrations of IFN-a, IFN-b, tumor
necrosis factor a (TNF-a), IL-6, and IL-12p40 (Figures 3B and
3C). In contrast, Siglec-H-deficient mice showed increased
amounts of serum cytokines after the injection with CpG-A
plus D-GalN, whereas pDC-ablated mice exhibited an enhanced
survival rate (p < 0.01), which was accompanied by a substantial
reduction in serum cytokine amounts (Figures 3B and 3C).
Taken together, these results indicate that pDCs initiate the
TLR9-mediated inflammation in vivo and Siglec-H regulates their
responsiveness to produce cytokines.
We further examined the TLR-mediated maturational changes
of cDCs and pDCs in vivo. Whereas the administration of CpG-A
increased the expression of MHC I (H-2Kb), MHC II, CD40, and
B7 family molecules on cDCs and pDCs in WT mice, their
amounts were further enhanced in Siglec-H-deficient mice (Fig-
ure S3). In addition, this treatment induced a more potent
expression of CD154 on pDCs in Siglec-H-deficient mice than
WT mice (Figure S3). In contrast, pDC-ablated mice exhibited
lower amounts of MHC and costimulatory molecules on cDCs
than WT mice (Figure S3).
Taken together, these results indicate that pDCs are involved
in the TLR9-mediated optimal maturation of cDCs in vivo and
that Siglec-H controls this process.
Siglec-H and pDCs Suppress Antigen-Specific CD4+ T
Cell Responses In Vivo
To determine the roles of Siglec-H and pDCs in antigen-specific
CD4+ T cell responses in vivo, carboxyfluorescein diacetate-
succinimidyl ester (CFSE)-labeled OT-II CD4+ T cells were adop-
tively transferred into mice, and their division was analyzed
3 days after systemic injection of soluble OVA protein under
steady-state conditions. Immunization with OVA protein resulted
in antigen-specific division of OT-II CD4+ T cells in WTmice (Fig-
ure 4A). When compared with WT mice, Siglec-H-deficient mice(D–K) CD45.1 OT-II CD4+ T cells (D, E, H, I) or CD45.1 OT-I CD8+ T cells (F, G, J,
Siglechdtr/dtr mice in the presence or absence of OVA protein (D, F, H, J), OVA323-33
by [3H]thymidine incorporation. The values for T cells alone and T cells plus DCs
*p < 0.01 compared with WT mice. Data are the mean ± SD, and the results are
Figure S1.
Iexhibited an enhancement of antigen-specific division of OT-II
CD4+ T cells, whereas pDC-ablated mice showed a vigorous
response of OT-II CD4+ T cells, and the reconstitution with WT
pDCs restored this response (Figures 4A and S4).
We next examined antigen-specific CD4+ T cell responses
under inflammatory conditions. At 14 days after immunization
with OVA protein emulsified in complete Freund’s adjuvant
(CFA), CD4+ T cells from pDC-ablated mice showed more
vigorous proliferation on restimulation with OVA protein than
did CD4+ T cells from Siglec-H-deficient mice, while both prolif-
erated more than those from WT mice (Figure 4B). Alternatively,
CD4+ T cells from Siglec-H-deficient mice substantially reduced,
whereas CD4+ T cells from pDC-ablated mice markedly
enhanced, the production of IFN-g as well as the frequency of
IFN-g-producing cells (Th1 cells), as compared with the cells
from WT mice (Figures 4C and 4D).
To assess the influence of the deficiency of Siglec-H and the
ablation of pDCs on the antigen-specific differentiation of CD4+
Foxp3 T cells into CD4+Foxp3+ inducible regulatory T (iTreg)
cells (Fukaya et al., 2010) under steady-state and inflammatory
conditions, we adoptively transferred OT-II CD4+Foxp3EGFP
T cells into mice and monitored the generation of OT-II CD4+
Foxp3EGFP+ iTreg cells 8 days after systemic immunization with
OVA protein (Figure 4E). In WT mice, immunization with OVA
protein generated OT-II CD4+Foxp3EGFP+ iTreg cells from OT-II
CD4+Foxp3EGFP T cells in steady-state conditions more than
in inflammatory conditions. In contrast, the peripheral generation
of OT-II CD4+Foxp3EGFP+ iTreg cells was reduced in Siglec-H-
deficient mice comparedwithWTmice after systemic immuniza-
tion, whereas it was severely diminished in pDC-ablated mice.
Collectively, these results indicate that pDCs inhibit antigen-
specific CD4+ T cell responses in vivo and that Siglec-H controls
their ability to generate CD4+ effector T (CD4+ Teff) cells and
CD4+Foxp3+ iTreg cells.
Siglec-H and pDCs Are Required for Antigen-Specific
CD8+ T Cell Responses In Vivo
To determine the contribution of pDCs and their Siglec-H-medi-
ated regulation to the cross-presentation of soluble antigen for
the activation of CD8+ T cells in vivo, mice that had been adop-
tively transferred with CFSE-labeled OT-I CD8+ T cells were
immunized with OVA protein, and antigen-specific division was
measured 3 days after immunization. In the steady state, WT
mice showed antigen-specific division of OT-I CD8+ T cells after
immunization with OVA protein (Figure 5A). Alternatively, pDC-
ablated mice and Siglec-H-deficient mice showed substantially
less antigen-specific division of OT-I CD8+ T cells than did WT
mice, and in pDC-ablated mice, the reduction in cell division
was overcome by reconstitution with WT pDCs (Figures 5A
and S5).
Next we examined the impact of the deficiency of Siglec-H
and ablation of pDCs on the generation of cytotoxic T lympho-
cytes (CTLs) through the cross-presentation of soluble antigen.K) were cultured with pDCs (D–G) or cDCs (H–K) obtained from WT mice and
9 peptide (E, I), or OVA257-264 peptide (G, K), and the proliferationwasmeasured
were less than 100 cpm.
representative of four independent experiments with similar results. See also
mmunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc. 961
Figure 2. Conditional Ablation of pDCs in Siglechdtr/dtr Mice
(A–C) WT mice (n = 6), Siglechdtr/+ mice (n = 6), and Siglechdtr/dtr mice (n = 6) were injected with DT (1 mg/mouse), and Spl, MLNs, and BM were obtained 2 days
after the injection.
(A) The frequency of CD11c+BST2+ pDCs was analyzed by flow cytometry. Data are represented by a dot plot, and numbers represent the proportion of
CD11c+BST2+ cells among leukocytes in each quadrant.
(B and C) The absolute number of CD11c+BST2+ pDCs (B) and CD11c+BST2 cDCs (C) was analyzed by flow cytometry.
(D) WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) were injected with various doses of DT, and Spl, MLNs, and BM were obtained 2 days after the injection. The
frequency of CD11c+BST2+ pDCs was analyzed by flow cytometry. Data are the percentage of positive cells among CD11c+ cells.
(E) WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) were injected with DT (1 mg/mouse), and Spl, MLNs, and BM were obtained at the indicated days after the
injection. The frequency of CD11c+BST2+ pDCs was analyzed by flow cytometry.
Data are the percentage of positive cells amongCD11c+ cells. *p < 0.01 comparedwithWTmice. Data are themean ± SD, and the results are representative of six
independent experiments with similar results. See also Figure S2.
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Figure 3. Deficiency of Siglec-H and Ablation of pDCs Affect TLR-Mediated Cytokine Production and Lethality
(A) WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) that had been treated with DT (1 mg/mouse) were injected with CpG-A complexed to in vivo-jetPEI transfection
reagent, and serum production of IFN-a (left) and IL-12p40 (right) was measured at the indicated time after injection by ELISA.
(B and C) WT mice (n = 10) and Siglechdtr/dtr mice (n = 10) that had been treated with DT (1 mg/mouse) were injected with CpG-A complexed to in vivo-jetPEI
transfection reagent plus D-GalN.
(B) Survival was monitored for 5 days.
(C) Serum production of IFN-a, IFN-b, TNF-a, IL-6, and IL-12p40 was measured at the indicated time after injection by ELISA.
*p < 0.01 compared with WT mice. Data are the mean ± SD, and the results are representative of three independent experiments with similar results. See
also Figure S3.
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Role of pDCs in Innate and Adaptive ImmunityMice were immunized with OVA protein combined with CpG-A
and CD40 mAb, and we quantified the generation of antigen-
specific CD8+ T cells based on binding with the MHC I-OVA
tetramer and intracellular expression of IFN-g aswell as their lytic
activity against OVA257-264 peptide-pulsed syngeneic spleno-Icytes 6 days after immunization (Figures 5B–5D). WT mice
showed efficient generation of MHC I-OVA tetramer+CD44hi
CD8+ T cells and CD8+IFN-g+ T cells as well as substantial
cytotoxic activity against targeted cells. In contrast, pDC-
ablated mice had a more dramatic reduction in the generationmmunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc. 963
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Figure 4. Deficiency of Siglec-H and Ablation of pDCs Affect Antigen-Specific CD4+ T Cell Responses In Vivo
(A) CD45.1+OT-II CD4+ T cells were transferred into WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) that had been treated with DT (1 mg/mouse), and then the mice
were immunized with OVA protein. Antigen-specific division of CD45.1+OT-II CD4+ T cells was analyzed at 3 days after the immunization by flow cytometry.
Data are represented by a histogram, and numbers represent the proportion of CFSE dilution among gated CD45.1+OT-II CD4+ T cells in each quadrant.
(B–D) WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) that had been treated with DT (1 mg/mouse) were immunized with CFA plus OVA protein.
(B and C) At 14 days after the immunization, Spl CD4+ T cells were cultured withWTCD11c+ DCs in the presence or absence of OVA protein for the measurement
of proliferative responses by [3H]thymidine incorporation (B) and production of IFN-g by ELISA (C).*p < 0.01 compared with WT mice. Data are the mean ± SD.
(D) Intracellular production of IFN-g in the cultured CD4+ T cells was analyzed by flow cytometry. Data are represented by a dot plot, and numbers represent the
proportion of IFN-g+ cells among gated CD4+ T cells in each quadrant.
(E) CD45.1+OT-II CD4+Foxp3EGFP T cells were transferred intoWTmice (n = 6) andSiglechdtr/dtr mice (n = 6) that had been treatedwith DT (1 mg/mouse), and then
the mice were immunized with OVA protein or CFA plus OVA protein. Expression of Foxp3EGFP among gated CD45.1+OT-II CD4+ T cells in Spl was analyzed at
8 days after the immunization by flow cytometry. Data are represented by a dot plot, and numbers represent the proportion of Foxp3EGFP+ cells among gated
CD45.1 OT-II CD4+ T cells in each quadrant.
The results are representative of three independent experiments with similar results. See also Figure S4.
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compared with WT mice.
Taken together, these results indicate that pDCs are involved
in the antigen-specific generation of CTLs in vivo, and Siglec-H
regulates their capacity to cross presentation of soluble antigen.
Siglec-H and pDCs Control the Homeostasis
of CD4+Foxp3+ Treg Cells and Th17 Cells In Vivo
To address the involvement of pDCs and their Siglec-H-medi-
ated regulation in the homeostasis of CD4+Foxp3+ Treg cells,
we analyzed the frequency and number of CD4+Foxp3+ Treg
cells in Siglec-H-deficient mice and pDC-ablated mice (Figures
6A–6C). Both had a slightly higher frequency and number of964 Immunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc.thymic CD4+Foxp3+ naturally occurring regulatory T (nTreg) cells
than did WT mice, whereas there was no difference in the
population of splenic CD4+Foxp3+ nTreg cells. In addition,
pDC-ablated mice, but not Siglec-H-deficient mice, displayed
a substantial reduction in CD4+Foxp3+ nTreg cells in the lamina
propria (LP) of the small intestine as compared with WT mice.
Previous studies have shown that IL-17-producing CD4+
T cells (Th17 cells) constitute a considerable proportion of
CD4+ T cells in LP in contrast to other peripheral lymphoid
tissues (Darrasse-Je`ze et al., 2009; Ohnmacht et al., 2009).
We therefore examined the roles of Siglec-H and pDCs in
the homeostasis of Th17 cells as well as Th1 cells in LP of the
small intestine (Figure 6D). Siglec-H-deficient mice showed a
AC D
B Figure 5. Deficiency of Siglec-H and Ablation
of pDCs Affect Antigen-Specific CD8+ T Cell
Responses In Vivo
(A) CD45.1+OT-I CD8+ T cells were transferred into WT
mice (n = 6) and Siglechdtr/dtr mice (n = 6) that had been
treated with DT (1 mg/mouse), and then the mice were
immunized with OVA protein. Antigen-specific division of
CD45.1+OT-I CD8+ T cells was analyzed at 3 days after the
immunization by flow cytometry. Data are represented by
a histogram, and numbers represent the proportion of
CFSE dilution among gated CD45.1+OT-I CD8+ T cells in
each quadrant.
(B–D)WTmice (n = 6) andSiglechdtr/dtr mice (n = 6) that had
been treated with DT (1 mg/mouse) were immunized with
CpG-A complexed to in vivo-jetPEI transfection reagent,
CD40 mAb, and OVA protein, and then a mixture of un-
pulsed CFSElo cells plus antigen-pulsed CFSEhi cells was
injected 5 days after the immunization. At 6 days after the
immunization, splenocytes were analyzed for the genera-
tion of MHC I-OVA tetramer+CD44hiCD8+ T cells (B), for
intracellular IFN-g-producing CD8+ T cells (C), and for
cytotoxic activity in vivo (D) by flow cytometry. Data are
represented by a dot plot (B and C), and numbers repre-
sent the proportion of MHC I-OVA tetramer+CD44hi cells
(B) and IFN-g+ cells (C) among gated CD8+ T cells in each
quadrant, or by a histogram (D), and numbers represent
the ratio of unpulsed CFSElo cells to antigen-pulsed
CFSEhi cells.
The results are representative of three independent
experiments with similar results. See also Figure S5.
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cells than did WT mice, whereas these populations were mark-
edly enhanced in pDC-ablated mice.
Collectively, these results indicate that pDCs are required for
the homeostasis of CD4+Foxp3+ Treg cells and CD4+ Teff cells
through the Siglec-H-mediated regulation in vivo.
Siglec-H and pDCs Control Host Defense against
Bacterial and Viral Infections In Vivo
The role of pDCs in the regulation of the host immune response
to bacterial infections in vivo is poorly understood. We therefore
examined the influence of a deficiency of Siglec-H and the abla-
tion of pDCs on inflammation caused by infection with Listeria
monocytogenes-expressing OVA (LM-OVA). WT mice exhibited
massive proinflammatory cytokine production 24 hr after infec-
tion with LM-OVA and died within 5 days of infection (Figures
7A and 7B), which was similar to microbial septic shock (Fujita
et al., 2006). In contrast, pDC-ablated mice were resistant to
lethal infection with LM-OVA with the decreased production of
proinflammatory cytokines as compared with WT mice (p <
0.01; Figures 7A and 7B). Furthermore, they showed a higher
absolute number of CD11c+B220 cDCs and lower bacterial
burden 3 days after infection with LM-OVA than WT mice
(Figures 7C and 7D).
To assess antigen-specific T cell responses against LM-OVA
in vivo, antigen-specific division of CFSE-labeled OT-II CD4+Immunity 35, 958–T cells or OT-I CD8+ T cells transferred into
mice was monitored 3 days after infection with
LM-OVA. Infection of WT mice caused
antigen-specific division of OT-II CD4+ T cellsand OT-I CD8+ T cells (Figures 7E and 7F). pDC-ablated mice
showed increased antigen-specific division of OT-II CD4+
T cells more than did Siglec-H-deficient mice when compared
withWTmice (Figure 7E). In contrast, pDC-ablated mice showed
substantially less antigen-specific division of OT-I CD8+ T cells
than did WT mice, whereas such cell division was slightly
reduced in Siglec-H-deficient mice (Figure 7F).
To clarify the role of pDCs and their Siglec-H-mediated regu-
lation in protective immune responses against viral infections,
we evaluated the production of serum cytokines and generation
of CTLs after infection with herpes simplex virus-1 (HSV-1).
Infection with HSV-1 triggered higher serum amounts of IFN-a
and IL-12p40 in Siglec-H-deficient mice than in WT mice 6 hr
after infection (Figure S6A). In contrast, the production of IFN-a
was markedly reduced in pDC-ablated mice, whereas only
a slight reduction in the production of IL-12p40 was observed
compared with WT mice after infection with HSV-1 (Figure S6A).
Alternatively, pDC-ablated mice exhibited a greater reduction in
the generation of MHC I-HSV-1 gB tetramer+CD44hiCD8+ T cells
and CD8+IFN-g+ T cells than in Siglec-H-deficient mice as
compared with WT mice 6 days after infection (Figures S6B
and S6C). Although we did not detect HSV-1 in Spl from WT
mice 6 days after infection, pDC-ablated mice had a higher viral
titer than did Siglech-H-deficient mice (Figure S6D).
Taken together, these results indicate that pDCs are involved
in the initiation of inflammation and antigen-specific T cell971, December 23, 2011 ª2011 Elsevier Inc. 965
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Figure 6. Deficiency of Siglec-H and Ablation of pDCs Affect the Homeostasis of CD4+Foxp3+ Treg Cells and Th17 Cells In Vivo
WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) were injected with DT (1 mg/mouse), and thymus (Thy), Spl, and LP were obtained 8 days after the injection.
(A–C) The proportion of CD4+Foxp3+ Treg cells among gated CD4+ T cells (top) and the absolute number (bottom) in Thy (A), Spl (B), and LP (C) was analyzed
by flow cytometry. Data are represented by a dot plot, and numbers represent the proportion of Foxp3+ cells among gated CD4+ T cells in each quadrant.
(D) The proportion of intracellular IFN-g- and IL-17-producing cells among gated CD4+ T cells (top) and the absolute number (bottom) in LP was analyzed by flow
cytometry. Data are represented by a dot plot, and numbers represent the proportion of IFN-g+ cells and IL-17+ cells among gated CD4+ T cells in each quadrant.
*p < 0.01 compared with WT mice. Data are the mean ± SD, and the results are representative of six independent experiments with similar results.
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Figure 7. Deficiency of Siglec-H and Ablation of pDCs Affect Host Defenses against Bacterial Infection In Vivo
(A–D) WT mice (n = 10) and Siglechdtr/dtr mice (n = 10) that had been treated with DT (1 mg/mouse) were uninfected or infected with LM-OVA.
(A) Survival was monitored for 10 days.
(B) Serum production of IFN-g, IL-6, and IL-12p40 was measured at 24 hr after infection by ELISA.
(C) The absolute number of CD11c+B220 cDCs was analyzed by flow cytometry 3 days after infection.
(D) Bacterial burden in the Spl was determined as colony-forming units (CFU) 3 days after infection.
*p < 0.01 compared with WT mice. Data are the mean ± SD.
(E and F) CD45.1+OT-II CD4+ T cells (E) or CD45.1+OT-I CD8+ T cells (F) were transferred into WT mice (n = 6) and Siglechdtr/dtr mice (n = 6) that had been treated
with DT (1 mg/mouse), and then the mice were infected with LM-OVA. Antigen-specific division of CD45.1+OT-II CD4+ T cells or CD45.1+OT-I CD8+ T cells was
analyzed at 3 days after infection by flow cytometry. Data are represented by a histogram, and numbers represent the proportion of CFSE dilution among gated
CD45.1+OT-II CD4+ T cells or CD45.1+OT-I CD8+ T cells in each quadrant.
The results are representative of three independent experiments with similar results. See also Figure S6.
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mediated regulation.
DISCUSSION
In this paper, we describe a DTR-based gene targeting strategy
that targets the Siglech gene and allows not only the effect of
a deficiency of Siglec-H to be analyzed but also the selective
elimination of pDCs in vivo. With those mice, we have demon-
strated the importance of the functions of pDCs and their Si-
glec-H-mediated regulation for the control of innate and adap-
tive immune responses in vivo.
Whereas several cell types have been reported to respond to
TLR9 ligand (Shen and Iwasaki, 2006), the contribution of pDCs
to the TLR9-mediated response in vivo remains unclear. Admin-
istration of anti-BST2 severely abolished TLR9-mediated
production of both IFN-a and IL-12 (Asselin-Paturel et al.,
2003; Kuwajima et al., 2006). Because BST2 expression could
be upregulated on the activated immune cells, this mAb could
deplete not only pDCs but also other leukocytes producing these
cytokines during inflammation (Swiecki and Colonna, 2010), re-
sulting in a profound reduction of TLR9-mediated responses
in vivo. Thus, pDCs could be the sole producer of type I IFN,
while they might moderately contribute to proinflammatory cyto-
kine release in response to TLR9 ligand, and Siglec-H directly
controls their responsiveness in vivo.
The deficiency of Siglec-H enhanced the maturation of cDCs,
whereas the ablation of pDCs reduced their changes after immu-
nization. Therefore, the cross-talk between pDCs and cDCs
could be important for the optimal activation of cDCs in vivo,
possibly mediated through the pDC-derived cytokine produc-
tion. Moreover, both the deficiency of Siglec-H and the ablation
of pDCs enhanced antigen-specific CD4+ T cell proliferation
in vivo. Collectively, these results imply that pDCs promote the
ability of cDCs to activate CD4+ T cells, whereas pDCs them-
selves suppress antigen-specific CD4+ T cell responses regard-
less of environmental conditions.
There has been some controversy regarding whether pDCs
are capable of priming and directing CD4+ T cell responses
in vivo (Villadangos and Young, 2008). In addition, the application
of BST2 mAb in vivo resulted in opposite effects on the genera-
tion of CD4+ Teff cells (Swiecki and Colonna, 2010), possibly
because of the variation in the types of cells depleted depending
on the progression of the immune response. The analysis of Si-
glec-H-deficient mice, however, indicates that pDCs have the
capacity to prime CD4+ T cells for the differentiation of CD4+
Teff cells and CD4+Foxp3+ iTreg cells through the Siglec-H-
mediated regulation of MHC II expression and cytokine produc-
tion. Alternatively, the results from pDC-ablated mice showed
that pDCs are required for the generation of CD4+Foxp3+ iTreg
cells. Taken together, our results support the notion that pDCs
promote the induction of peripheral tolerance mediated by the
generation of antigen-specific CD4+Foxp3+ iTreg cells and
dampen antigen-specific CD4+ Teff cell responses elicited by
cDCs in vivo.
Although the cross-presentation of exogenous antigens in
CD4CD8a+ cDCs for the priming of CD8+ T cells to elicit CTL
immunity has been described (Dudziak et al., 2007; Hildner
et al., 2008), the contribution of pDCs to this process in vivo968 Immunity 35, 958–971, December 23, 2011 ª2011 Elsevier Inc.remains under debate (Mourie`s et al., 2008; Villadangos and
Young, 2008). Although the depletion of pDCs in vivo with
BST2 mAb blocked the induction of CTLs (Honda et al., 2005),
this might not exclude the involvement of cDCs because they
are able to express BST2 after activation (Swiecki and Colonna,
2010). Our findings, however, strongly support the pivotal
function in vivo of pDCs as APCs in activating CD8+ T cells
through cross-presentation, which is different from the evidence
that pDCs are less efficient at cross-presentation than cDCs
in vitro. This difference might be explained by the notion that
an environmental factor or encountered stimulus prolongs the
life span of pDCs and enhances their capacity for cross-presen-
tation. Alternatively, the induction of CTLs by CD40/TLR trig-
gering was reportedly dependent on B7-mediated costimulation
and type I IFN in vivo (Ahonen et al., 2004). Furthermore, the
interaction between pDCs and cDCs through CD154/CD40
was required for the licensing of cDCs to prime CTL immunity
in vitro (Yoneyama et al., 2005). However, the enhanced expres-
sion of CD154 on pDCs could be insufficient for the generation of
CTLs when there is a deficiency of Siglec-H in vivo. Taken
together, pDCs could be required for the efficient priming of
CD8+ T cells leading to the generation of CTLs in vivo through
the Siglec-H-mediated control of cross-presentation as well as
the production of type I IFN and the expression of CD154 for
the activation of cDCs.
Published reports suggested that development of CD4+
Foxp3+ nTreg cells is required for interaction of CD4+Foxp3
thymocytes with thymic medullary epithelial cells (mTECs) and
cDCs (Proietto et al., 2008; Hinterberger et al., 2010). In contrast,
our results indicate that pDCs appear to negatively regulate the
development of thymic CD4+Foxp3+ nTreg cells. Thus, pDCs
could interfere with the differentiation of thymic CD4+Foxp3+
nTreg cells bymTECs and cDCs, and Siglec-H-mediated regula-
tion of MHC II expression and cytokine production might
contribute to this phenomenon.
cDCs are involved in homeostatic expansion of CD4+Foxp3+
nTreg cells and generation of CD4+Foxp3+ iTreg cells in periph-
eral and mucosal tissues (Kretschmer et al., 2005; Darrasse-
Je`ze et al., 2009; Fukaya et al., 2010). Our results clearly suggest
that pDCs are involved in mucosal homeostasis of CD4+Foxp3+
nTreg cells, although they are dispensable for peripheral homeo-
stasis of CD4+Foxp3+ nTreg cells. Furthermore, the mucosal
generation of antigen-specific CD4+Foxp3+ iTreg cells was
severely impaired in the absence of pDCs during the oral priming
of antigen (data not shown). These observations imply that pDCs
participated in de novo generation of CD4+Foxp3+ iTreg cells in
mucosal tissues when they encountered food antigens and
commensals under steady-state conditions. Previous studies
have suggested that pDCs play a key role in airway tolerance
and oral tolerance by inducing the generation of Treg cells as
well as deletion and anergy of CD4+ Teff cells (de Heer et al.,
2004; Goubier et al., 2008). Therefore, these results suggest
that pDCs are crucial for inducing antigen-specific dominant
and recessive tolerance to maintain mucosal immune
homeostasis.
Mucosal cDCs are suggested to participate in the differentia-
tion of Th17 cells (Darrasse-Je`ze et al., 2009; Ohnmacht et al.,
2009). Analyses of Th1 cells and Th17 cells in LP of Siglec-H-
deficient mice indicate that Siglec-H regulates the capacity of
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Furthermore, the engagement of type I IFN receptors expressed
by DCs reportedly blocked their ability to generate Th17 cells
(Shinohara et al., 2008). Thus, inefficient CD4+ T cell priming
and robust production of type I IFN by pDCs might explain the
impaired generation of LP CD4+ Teff cells under Siglec-H-defi-
cient conditions. More importantly, the results from pDC-ablated
mice suggest that pDCs block the differentiation of CD4+ Teff
cells through preferential generation and expansion of CD4+
Foxp3+ Treg cells, revealing a pDC-mediated regulatory loop
for maintaining immune equilibrium in mucosal tissues.
cDCs have been suggested to control host defenses against
intracellular bacterial infections (Jung et al., 2002; Zammit
et al., 2005; Neuenhahn et al., 2006). Analysis of pDC-ablated
mice suggests that pDCs play a critical role in the initiation and
amplification of proinflammatory cytokine production leading
to septic shock during early massive bacterial infections.
Although cDCs have been described as crucial for inhibiting early
bacterial growth (Neuenhahn et al., 2006), dysregulated inflam-
mation reportedly induced a systemic loss of cDCs during bacte-
rial sepsis (Efron et al., 2004). Therefore, the retention of cDCs
during the reduced inflammation in the absence of pDCs might
explain the effective bacterial clearance. In contrast, pDCs
appear to limit antibacterial CD4+ T cell responses, whereas
they are required for optimal antibacterial CD8+ T cell responses
through the Siglec-H-mediated regulation. It has been sug-
gested that bacterial antigen-specific CD8+ T cells are crucial
for eliminating pathogenic microbes (Neuenhahn et al., 2006).
Thus, pDCs might contribute to the establishment of the protec-
tive immunity against bacterial infections mediated by the cross-
priming of antibacterial CTLs. Taken together, our findings indi-
cate the multiple roles of pDCs in the control of inflammation
and T cell responses triggered by bacterial infections.
Whereas pDCs have been suggested to be important media-
tors of host protective immunity against viral infections through
their ability to produce type I IFN (Shen and Iwasaki, 2006; Gilliet
et al., 2008), how pDCs contribute to the antiviral immune
response in vivo remains unclear. A study on the depletion of
pDCs and other leukocytes with mAbs to Gr-1 and BST2 sug-
gested a potential helper function of pDCs, aiding the ability of
cDCs to prime antiviral CTLs (Yoneyama et al., 2005). Further-
more, a recent study with human blood dendritic cell antigen 2
(BDCA-2)-DTR transgenic mice suggested that pDCs mediate
early antiviral type I IFN responses that control viral replication,
and this control of viral burden influences the accrual of virus-
specific NK or CD8+ T cells (Swiecki et al., 2010). In contrast,
analyses of Siglec-H-deficient mice and pDC-ablated mice
suggest that pDCs are the main producer of type I IFN, although
they make a minimal contribution to proinflammatory cytokine
production under the control of Siglec-H during the initial stages
of HSV-1 infection in vivo. Furthermore, our results demonstrate
the impaired generation of HSV-1-specific CTLs despite the
opposite effect on the production of type I IFN. These findings
led us to hypothesize that the ability of pDCs to cross-present
viral antigen, in addition to their known function as a source of
type I IFN, is necessary for the efficient induction of antiviral
CTL responses to eliminate viruses.
In conclusion, we described a crucial role of pDCs in the regu-
lation of inflammation and antigen-specific T cell responsesIin vivo and further showed that Siglec-H provides the fine-tuning
of their function. Further elucidation of pDC function might
provide critical insight into immune regulation and pathology
and aid therapeutic interventions for autoimmune and inflamma-
tory disorders as well as infectious diseases.
EXPERIMENTAL PROCEDURES
Standard methods are described in Supplemental Experimental Procedures.
Mice
The following mice were used in this study: 8- to 12-week-old C57BL/6 mice
(Charles River Laboratories), B6.OT-I TCR transgenic mice harboring OVA-
specific CD8+ T cells (Dudziak et al., 2007; Hildner et al., 2008), and B6.OT-II
TCR transgenic mice harboring OVA-specific CD4+ T cells (Dudziak et al.,
2007; Hildner et al., 2008). B6.CD45.1+ OT-I mice and B6.CD45.1+ OT-II
mice were bred in-house by crossing B6.OT-I mice and B6.OT-II mice with
CD45.1+ B6 mice. Foxp3EGFPCD45.1+ OT-II mice were also generated by
crossing B6.CD45.1+ OT-II mice with B6.Foxp3EGFP mice (Wang et al.,
2008). The generation of Siglechdtr/dtr mice is detailed in Supplemental Exper-
imental Procedures. The mutant mice were cross-mated for more than nine
generations with C57BL/6 mice, and Siglech+/+ littermates were used as WT
mice. All mice were bred and maintained in specific-pathogen-free conditions
in the animal facility at RIKEN Research Center for Allergy and Immunology in
accordance with institutional guidelines.
In Vivo TLR Stimulation
Mice were intravenously (i.v.) injected with 10 mg of CpG-A oligodeoxynucleo-
tide (ODN) (D19, ggTGCATCGATGCAgggggG; Sigma Aldrich) complexed to
10 ml of in vivo-jetPEI transfection reagent (Polyplus transfection) with or
without a peritoneal (i.p.) injection of D-GalN (20 mg/mouse; Sigma-Aldrich).
Survival was then monitored for 5 days or sera were collected at the indicated
times. In some experiments, Spl was obtained from the mice 24 hr after
injection.
Immunization
For the analysis of antigen-specific CD4+T cell responses, mice were immu-
nized subcutaneously (s.c.) with 100 mg of OVA protein (Sigma-Aldrich) emul-
sified in CFA (Difco), and the Spl was obtained 14 days after the immunization.
For the generation of antigen-specific CTLs (Ahonen et al., 2004), mice
received an i.v. injection of 10 mg of CpG-A ODN complexed to 10 ml of in vivo-
jetPEI transfection reagent in combination with an i.p. injection of 500 mg of
OVA protein plus 10 mg of CD40 mAb (clone 1C10; eBioscience), and Spl
was obtained from the mice 6 days later.
Statistical Analysis
Data are expressed as themean ± SD. The statistical significance of the values
obtained was evaluated by ANOVA and the Kaplan-Meier log-rank test. A p
value of <0.01 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.
immuni.2011.10.014.
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